β-defensin 22 Inhibitors
β-defensin 22 inhibitors represent a unique class of molecules that interact with β-defensin 22, a member of the defensin family of antimicrobial peptides. Defensins are small, cysteine-rich proteins found in a variety of organisms, ranging from humans to insects. Structurally, β-defensin 22 exhibits a conserved disulfide-linked structure that stabilizes its three-dimensional conformation. Inhibitors of β-defensin 22 are typically designed or identified to bind specifically to this peptide, disrupting its natural structural integrity or modulating its ability to interact with other biological components. These inhibitors may target key regions within the β-defensin 22 peptide, such as its positively charged surface or the cysteine-stabilized loops, leading to alterations in its molecular function. The inhibitors can be small organic molecules, peptides, or even larger protein-based inhibitors, all designed to interact with the precise folding patterns and binding sites of β-defensin 22.
Research into β-defensin 22 inhibitors delves into the structural dynamics of both the inhibitor and the target peptide. These studies often involve advanced biophysical techniques like nuclear magnetic resonance (NMR), X-ray crystallography, and molecular modeling to understand the binding affinities, conformational changes, and mechanistic details of inhibition. Computational docking studies and molecular dynamics simulations play an integral role in predicting how various inhibitors may interact with β-defensin 22 at the atomic level. This helps researchers elucidate the key binding interactions and optimize inhibitor design. Moreover, the development of these inhibitors often requires an understanding of the chemical environment in which β-defensin 22 operates, including its interaction with membranes, ions, and other proteins. Consequently, β-defensin 22 inhibitors are a focal point for understanding molecular interactions and biochemical pathways, making them a valuable subject of biochemical research.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Inhibitor of NF-κB pathway indirectly suppressing β-defensin 22. Triptolide inhibits NF-κB, leading to downregulated β-defensin 22 expression. By preventing NF-κB translocation to the nucleus, it disrupts the transcriptional regulation of β-defensin 22. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
p38 MAPK inhibitor impacting β-defensin 22 through the p38 MAPK pathway. SB203580 inhibits p38 MAPK, disrupting downstream signaling events. By preventing p38-mediated events, it alters the transcriptional regulation of β-defensin 22 in response to extracellular signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor influencing β-defensin 22 through the mTOR pathway. Rapamycin inhibits mTOR, disrupting downstream signaling events. This interference alters the translation and transcription processes associated with β-defensin 22 regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor affecting the PI3K/Akt pathway. By blocking Akt activation, LY294002 indirectly influences β-defensin 22 expression. This disruption of the PI3K pathway alters downstream signaling events, leading to the downregulation of β-defensin 22. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor influencing the TGF-β signaling pathway. SB431542 indirectly downregulates β-defensin 22 by blocking TGF-β receptor activation. This prevents the transduction of signals that would otherwise contribute to β-defensin 22 regulation. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
AMPK activator influencing β-defensin 22 through the AMPK pathway. A769662 activates AMPK, which then inhibits mTOR. This cascade of events alters the translation and transcription processes associated with β-defensin 22, leading to its downregulation. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
JAK inhibitor impacting β-defensin 22 through the JAK/STAT pathway. By inhibiting JAK, it disrupts downstream STAT activation, altering the transcriptional regulation of β-defensin 22. The inhibition of JAK prevents the events that contribute to β-defensin 22 upregulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor influencing β-defensin 22 through the JNK pathway. SP600125 inhibits JNK, leading to altered transcriptional regulation of β-defensin 22. By preventing c-Jun phosphorylation, a downstream target of JNK, it downregulates β-defensin 22 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Selective MEK inhibitor impacting β-defensin 22 through the MAPK/ERK pathway. PD98059 inhibits MEK, disrupting downstream ERK activation. This interference alters the transcriptional regulation of β-defensin 22 in response to extracellular signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor influencing β-defensin 22 through the PI3K/Akt pathway. Wortmannin inhibits PI3K, blocking Akt activation and disrupting downstream signaling events. This alteration leads to the downregulation of β-defensin 22 at the transcriptional level. | ||||||